What is Spero Therapeutics Return-on-Tangible-Equity?
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Spero Therapeutics's annualized net income for the quarter that ended in Sep. 2024 was $-68.59 Mil. Spero Therapeutics's average shareholder tangible equity for the quarter that ended in Sep. 2024 was $73.00 Mil. Therefore, Spero Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2024 was -93.95%.
The historical rank and industry rank for Spero Therapeutics's Return-on-Tangible-Equity or its related term are showing as below:
SPRO'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -5180.61 Med: -75.77 Max: 24.95
Current: 4.36
During the past 9 years, Spero Therapeutics's highest Return-on-Tangible-Equity was 24.95%. The lowest was -5,180.61%. And the median was -75.77%.
SPRO's Return-on-Tangible-Equity is ranked better than 84% of 1256
companies
in the Biotechnology industry
Industry Median: -48.155
vs SPRO: 4.36
Spero Therapeutics Return-on-Tangible-Equity Historical Data
The historical data trend for Spero Therapeutics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Spero Therapeutics's Return-on-Tangible-Equity
For the Biotechnology subindustry, Spero Therapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spero Therapeutics's Return-on-Tangible-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spero Therapeutics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Spero Therapeutics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Sep. 2024) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Spero Therapeutics Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of Spero Therapeutics's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SPRO has been successfully added to your 